Vanda Pharmaceuticals Inc.
VNDA · XNASCIK 1347178fmd_08EX25TX8KF1KAX0P84V1Y42WSManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 146 | 165 | 193 | 227 | 248 | 269 | 254 | 193 | 199 | 216 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 29 | 39 | 44 | 49 | 56 | 75 | 86 | 77 | 74 | 109 |
| Selling, general and administrative | 100 | 124 | 106 | 130 | 141 | 124 | 136 | 113 | 146 | 238 |
| Operating income | (19) | (17) | 22 | 23 | 27 | 42 | 6 | (14) | (41) | (151) |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | (18) | (15) | 25 | 29 | 32 | 42 | 11 | 6 | (23) | (139) |
| Income tax expense | 0 | 0 | 0 | (87) | 8 | 9 | 5 | 4 | (4) | 82 |
| Net income from continuing operations | (18) | (16) | 25 | 116 | 23 | 33 | 6 | 3 | (19) | (220) |
| Net income | (18) | (16) | 25 | 116 | 23 | 33 | 6 | 3 | (19) | (220) |